702 filings
Page 2 of 36
8-K
6onqbwh
2 Jun 23
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
4:28pm
8-K
9e8xizh3e0spq6bv1q
1 Jun 23
Other Events
5:17pm
8-K
sx322f
31 May 23
Other Events
5:07pm
8-K
gu0nyq96m5kys
11 May 23
Acorda Therapeutics Reports First Quarter 2023 Financial Results
4:15pm
8-K
eynkgnf1q64phrh6p9
10 May 23
Other Events
8:00am
8-K
qfl8n1u1wz29ea4
8 May 23
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
5:16pm
ARS
ezk42 wa0vy9
27 Apr 23
Annual report to shareholders
8:49pm
DEFA14A
1572xd6do5tpelmg6g
27 Apr 23
Additional proxy soliciting materials
5:26pm
8-K
qam0q7
16 Mar 23
Other Events
8:16pm
8-K
wfvao5v3
9 Mar 23
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
7:38am
8-K
d6x4m4vc2lvx ufv
15 Feb 23
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
11:18am
8-K
cskdncdfm
5 Jan 23
2026 manufacturing capacity expansion expected to result in further reductions in cost of goods
5:14pm
8-K
egmcuk0c689lzm8z
23 Dec 22
Regulation FD Disclosure
8:49am
8-K
qco8o7
22 Dec 22
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
8:15am
8-K
qr6 s1c4e5d9stla0r
21 Dec 22
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
7:00am
8-K
ri6ijxde5w7 pv
5 Dec 22
Other Events
8:00am